One price, any dose
The flat rate is stated twice on the priced page, once beside the words any dose, same price, and once at the foot of the plan block. A three-month programme is offered at the same per-month figure, billed monthly in three payments and discounted from a stated higher monthly rate.
A flat rate matters more here than it does in most categories, because GLP-1 dosing steps up over months. A seller that charges by strength can quote an entry figure and bill twice that by month five. This one says it will not, and the plan block is consistent with the claim.
The five states it names, and the list it does not
Directly beneath the plan block sits a sentence naming five states, by their postal codes, in which the seller is unable to dispense tirzepatide at this time. Naming an exclusion is unusual and useful.
It is not, however, a service area. Nothing on the site lists where the service is available, for either drug. We have recorded no state list on that basis: one hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all, and an exclusion list does not move a seller out of that group. The site's own shop filter compounds the question by listing a state as a product audience, which suggests state-specific stock that the coverage copy never describes.
The sentence that undercuts the page
Lower down, a comparison paragraph contrasts brand-name pricing with this seller's own and states that its compounded GLP-1 programmes start at a figure. That figure is roughly half the flat rate printed at the top of the same page, and no plan on the page sells at it.
We have recorded the plan figures and put the comparison figure in the first row's qualifier. There is no way to tell from the page which one a buyer would be charged, and the seller has not resolved it.
What the page does do properly is name a clinician: a naturopathic doctor with her credential, her focus, and a link to a full biography. Fifty of the one hundred and fifty-eight sellers here name an individual clinician, and this is one of them. No compounding pharmacy is named; the page says FDA-inspected pharmacies, which is a category. One hundred and twenty-six of the one hundred and fifty-eight sellers here name none.
Heva Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $339/moper month, any dose at the same price; the same page states in a comparison paragraph that its compounded GLP-1 programs start at $174/month, which no plan on the page sells at | September 2026source |
| Semaglutide (compounded) | $339/moper month on the 3-month program, billed monthly in three payments, discounted from a stated $399/mo | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Heva Health's current price →Good fit if
- Buyers who want one price that holds at every dose, stated as such.
- Readers who want a named clinician with a credential and a biography rather than a reference to licensed providers.
- People in the five states where tirzepatide is unavailable, who would rather be told before they start an intake.
Look elsewhere if
- Anyone who needs the seller's own copy to agree with itself. A comparison paragraph on the priced page states a starting figure no plan sells at.
- Readers who want a positive service-area list rather than an exclusion.
- Buyers who want the compounding pharmacy named.
- People looking for a brand-name route; there is none.
How this review was verified
- Re-read the weight-loss page and the terms of service on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Recorded the plan figures and the conflicting comparison figure both, rather than choosing between them, and stored the comparison figure inside the first price row's qualifier.
- Read the exclusion sentence in full and recorded it as an exclusion rather than converting it into a coverage list.
- Set the membership status from the Terms, which describe the programme as membership-based and define the membership fee as the thing the patient pays, alongside the priced page's statement of what the figure covers.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.